Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

Autor: Van Cutsem, Eric, Peeters, Marc, Van den Evnde, Marc, André, Thierry, Borg, Christophe, Sarabi, Matthieu, Ghiringhelli, Francois, Chibaudel, Benoist, Siena, Salvatore, Cremolini, Chiara, Zampino, Maria G., Elez, Elena, Keranen, Susana R., Salazar, Ramon, Alfonso, Pilar, Strickler, John H., Cercek, Andrea, Ng, Kimmie, Wu, Christina, Paulson, Andrew S., Hubbard, Joleen M., Coveler, Andrew L., Fountzilas, Christos, Kardosh, Adel, Kasi, Pashtoon M., Lenz, Heinz-Josef, Ciombor, Kristen K., Bajor, David L., Bekaii-Saab, Tanios S., Gbolahan, Olumide, Boland, Patrick, Berg, Daniel, Sanchez, Federico, Goggins, Timothy, Saeed, Anwar, Burris, Howard, Bendell, Johanna, Outlaw, Darryl, Tafur, Isaac, Shergill, Ardaman, Catenacci, Daniel, Gong, Jun, Garrido-Laguna, Ignacio, Finley, Gene, Weinberg, Benjamin, Shields, Anthony, Philip, Philip, Turk, Anita, Nguyen, Anthony, Braiteh, Fadi, Patel, Vijay, Harwin, William, Anderson, Ian, Kundra, Ajay, Chen, Christopher, Ford, James, Kundranda, Madappa, Nguyen, Danny, Ratnam, Suresh, Richards, Donald, Nallapareddy, Sujatha, Beeram, Sridhar, McKenney, Scott, Shao, Spencer, Strickler, John H, Paulson, Andrew S, Hubbard, Joleen M, Coveler, Andrew L, Kasi, Pashtoon M, Ciombor, Kristen K, Bajor, David L, Stecher, Michael, Feng, Wentao, Bekaii-Saab, Tanios S ^*

Publikováno v: In The Lancet Oncology May 2023 24(5):496-508

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study

Autor: Bekaii-Saab, Tanios S, Ou, Fang-Shu, Ahn, Daniel H, Boland, Patrick M, Ciombor, Kristen K, Heying, Erica N, Dockter, Travis J, Jacobs, Nisha L, Pasche, Boris C, Cleary, James M, Meyers, Jeffrey P, Desnoyers, Rodwige J, McCune, Jeannine S, Pedersen, Katrina, Barzi, Afsaneh, Chiorean, E Gabriela, Sloan, Jeffrey, Lacouture, Mario E, Lenz, Heinz-Josef, Grothey, Axel

Publikováno v: In The Lancet Oncology August 2019 20(8):1070-1082

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Autor: Le, Dung T., Durham, Jennifer N., Smith, Kellie N., Wang, Hao, Bartlett, Bjarne R., Aulakh, Laveet K., Lu, Steve, Kemberling, Holly, Wilt, Cara, Luber, Brandon S., Wong, Fay, Azad, Nilofer S., Rucki, Agnieszka A., Laheru, Dan, Donehower, Ross, Zaheer, Atif, Fisher, George A., Crocenzi, Todd S., Lee, James J., Greten, Tim F., Duffy, Austin G., Ciombor, Kristen K., Eyring, Aleksandra D., Lam, Bao H., Joe, Andrew, Kang, S. Peter, Holdhoff, Matthias, Danilova, Ludmila, Cope, Leslie, Meyer, Christian, Zhou, Shibin, Goldberg, Richard M., Armstrong, Deborah K., Bever, Katherine M., Fader, Amanda N., Taube, Janis, Housseau, Franck, Spetzler, David, Xiao, Nianqing, Pardoll, Drew M., Papadopoulos, Nickolas, Kinzler, Kenneth W., Eshleman, James R., Vogelstein, Bert, Anders, Robert A., Diaz, Luis A.

Publikováno v: Science, 2017 Jul . 357(6349), 409-413.

Externí odkaz: https://www.jstor.org/stable/26399525

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.